ARCHIMED to Acquire Esperion Therapeutics for Cash and Contingent Value Rights
ARCHIMED will acquire Esperion Therapeutics for $3.16 per share in cash. Shareholders will also receive one non-tradeable contingent value right. This right allows holders to receive up to $100 million in aggregate milestone payments based on future U.S. product sales.
The deal is expected to close in the third quarter of 2026. Closing is subject to regulatory approvals and a shareholder vote. A virtual special meeting for stockholders is scheduled for July 8, 2026.
Key Takeaways
- Esperion shareholders will receive $3.16 per share in cash at closing.esperion.com+1stocktitan.net
- The deal includes a non-tradeable contingent value right providing up to $100 million in payments based on product sales.esperion.com+1
- Financing for the acquisition totals $1.08 billion, consisting of $706.1 million in equity and $550 million in debt.esperion.comstocktitan.net
- The transaction is expected to close in Q3 2026, with a shareholder vote scheduled for July 8, 2026.esperion.com+1
- Total equity value of the transaction is approximately $1.1 billion.reuters.com
Sources
Archimed to take Esperion Therapeutics private in $1.1 billion deal
Reuters
“The report specifies the total deal value is up to $1.1 billion.”
Esperion Therapeutics to be Acquired for $3.16 Per Share Plus CVR
StockTitan
“The source summarizes the SEC filing and provides the acquisition price and CVR details.”
DEFM14A Merger Proxy Statement
Esperion
“The filing details the specific CVR milestones for bempedoic acid and ENBUMYST and the $1.08 billion financing structure.”